In a nutshell This study examined if nutritional supplements can reduce the rate of hypoglycemia in patients with Type 2 diabetes (T2D). This study concluded that these supplements helped reduce hypoglycemia and lowered mortality risk for these patients. Some background Treatment for T2D, such as insulin, can cause blood sugar levels to...
Read More
In a nutshell This study wanted to evaluate the safety and effectiveness of bexagliflozin in patients with type 2 diabetes (T2D). The study found that this treatment was safe and significantly improved the outcomes of these patients. Some background Bexagliflozin is a new medication for treating T2D. It is part of a larger class of...
Read More
In a nutshell The aim of this study was to assess the remission of type 2 diabetes (T2D) during a family doctor-led weight management programme. The main finding of the study was that after 2 years of the programme more than one-third of patients had reversed their T2D. Some background The number of people with T2D is increasing. One factor is the...
Read More
In a nutshell The aim of this study was to investigate the effect of SGLT2 inhibitors on the prevention of heart and kidney disease in patients with type 2 diabetes (T2D). The main outcome was that SGLT2-inhibitors reduced hospitalization for heart failure and prevented the worsening of kidney disease in T2D. Some background There are many...
Read MoreIn a nutshell The aim of this study is the test the effectiveness of new drug BTI320 on blood glucose control in type 2 diabetes (T2D). The main outcome to be measured will be a change in blood glucose 2 hours after meals. This study is being carried out in the United States. The details The number of patients with T2D is constantly on the rise....
Read More
In a nutshell The aim of this study was to evaluate how safe and effective ertugliflozin (Steglatro) is in patients with type 2 diabetes (T2D) that is not controlled well with metformin (Glucophage). The study found that ertugliflozin is safe and improved blood glucose control, body weight, and blood pressure in these patients. Some background...
Read More
In a nutshell This study evaluated the safety and effectiveness of adding sitagliptin (Januvia) to treatment with pre-mixed insulin in patients with poorly controlled Type 2 diabetes (T2D). This study concluded that sitagliptin was well-tolerated and significantly improved glycemic (blood sugar) control in these patients. Some background As...
Read More
In a nutshell This study evaluated the risk of genital infections in patients with Type 2 diabetes (T2D) treated with SGLT2 (sodium-glucose cotransporter 2) inhibitors. This study concluded that this therapy was associated with a 3-fold higher risk of genital infections in these patients. Some background SGLT2 inhibitors help the kidneys remove...
Read More
In a nutshell This study investigated the long-term effects of ipragliflozin (Suglat) in people with type 2 diabetes (T2D). It was determined that ipragliflozin showed long-term beneficial effects on blood glucose control, weight, and kidney function. Some background Ipragliflozin is an SGLT2 inhibitor. SGLT2 inhibitors are medications for T2M that...
Read More
In a nutshell This study evaluated the safety of a combination of empagliflozin (Jardiance) and linagliptin (Tradjenta) compared to either drug on its own, in people with type 2 diabetes (T2D). It was determined that the combination was as safe as either drug alone. Some background Metformin (Glucophage) is usually the first drug given to...
Read MoreIn a nutshell This study evaluated the effects on cardiovascular disease (CVD) of SGLT2 inhibitors compared to two other drugs used to treat type 2 diabetes (T2D), sulfonylureas, and DPP4 inhibitors. It was determined that SGLT2 inhibitors were associated with a lower risk of developing CVD. Some background People with T2D have an increased risk of...
Read More
In a nutshell This study investigated whether strict control of blood glucose levels (glycemic control) increases mortality (risk of death) in older adults with type 2 diabetes (T2D). It was determined that tight glycemic control increases the mortality risk in such persons when it is achieved with metformin (Glucophage), sulfonylureas, or insulin. Some...
Read More
